Xalud Therapeutics
New York
About Xalud Therapeutics
Xalud Therapeutics is a biotech company that develops therapies for the treatment of neuro-inflammatory diseases. It offers a gene therapy platform that addresses chronic pain. The lead product candidate, XT-150 is in two P2 clinical studies for the treatment of Osteoarthritis Pain. Xalud is a portfolio company of PBM Capital Group. The company was established in 2009 and is based in San Francisco, California, United States.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: Less than $1M
- Total funding: $42.3M
- Funding stage: Late Stage Venture
- Last round: Series C (Aug 2021)
- Website: xaludthera.com
- Phone: (434) 980-8105
Industries & Categories
Biotechnology, Health Care, Medical, Neuroscience, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/xalud-therapeutics-43184 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.